The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Event-free survival with adjuvant selpercatinib in stage IB-IIIA RET fusion-positive NSCLC: Primary results of the phase 3 LIBRETTO-432 trial.
 
Jonathan Goldman
Honoraria - Abbvie; AstraZeneca; Genentech; Lilly; Summit Therapeutics
Consulting or Advisory Role - AbbVie; AstraZeneca; Genentech; Lilly; Summit Biomedical
Research Funding - Abbvie (Inst); Advaxis (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Lilly (Inst); Lyell Immunopharma (Inst); Pfizer (Inst); Summit Biomedical (Inst); Systimmune (Inst)
Travel, Accommodations, Expenses - Summit Therapeutics
 
Xuening Yang
No Relationships to Disclose
 
Maximilian Hochmair
No Relationships to Disclose
 
Lin Wu
No Relationships to Disclose
 
Hye Ryun Kim
Honoraria - AstraZeneca; MSD Oncology
Consulting or Advisory Role - AstraZeneca; BeiGene
Speakers' Bureau - ABL Bio; AstraZeneca; MSD Oncology; Ono Pharmaceutical; Roche/Genentech; Yuhan
Research Funding - AstraZeneca (Inst); Yuhan (Inst)
 
Luis Paz-Ares
Leadership - ALTUM Sequencing; Stab Therapeutics
Stock and Other Ownership Interests - Altum Sequencing; Stab therapeutics
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; BeOne; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Janssen; Lilly; Medscape; Merck Serono; MSD; Novartis; Pfizer; PharmaMar; Regeneron; Roche/Genentech; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; AstraZeneca; Bayer; BMS; GlaxoSmithKline; Janssen; Lilly; Merck; Mirati Therapeutics; MSD; Novartis; Pfizer; Pharmamar; Regeneron; Roche; Sanofi; Takeda
Speakers' Bureau - Amgen; AstraZeneca; Beone; BMS; Daiichi Sankyo Europe GmbH; Lilly; Merck Serono; MSD Oncology; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); BMS (Inst); MSD (Inst); Pfizer (Inst); PharmaMar (Inst)
Other Relationship - Amgen (I); Astellas Pharma (I); Crinetics Pharmaceuticals (I); Esteve (I); HUTCHMED (I); Ipsen (I); ITM Isotope Technologies Munich (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I)
 
Damian Rieke
Employment - Charité - Universitätsmedizin Berlin
Honoraria - Bayer; Bristol-Myers Squibb; Lilly; Roche
Consulting or Advisory Role - Bayer; BeiGene
Research Funding - Seagen
Travel, Accommodations, Expenses - Bayer; Johnson & Johnson/Janssen
 
Melissa Johnson
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BeOne Medicines (Inst); Biohaven Pharmaceuticals (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Merck (Inst); Nuvalent, Inc. (Inst); Ottimo Pharma (Inst); Pfizer (Inst); Regeneron (Inst); Revolution Medicines (Inst); Summit Therapeutics (Inst); Zai Lab (Inst)
Research Funding - Adaptimmune (Inst); Amgen (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); Bayer (Inst); Black Diamond Therapeutics (Inst); BlossomHill Therapeutics (Inst); Boehringer Ingelheim (Inst); Boundless Bio (Inst); Bristol-Myers Squibb (Inst); Carisma Therapeutics (Inst); Conjupro Biotherapeutics (Inst); Corvus Pharmaceuticals (Inst); D3 Bio (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); Harpoon (Inst); Helsinn Healthcare (Inst); IDEAYA Biosciences (Inst); IGM Biosciences (Inst); Immuneering (Inst); Immunitas (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Lilly (Inst); LockBody Therapeutics (Inst); Loxo (Inst); Merck (Inst); Merus (Inst); Mirati Therapeutics (Inst); Modex Therapeutics (Inst); Mythic Therapeutics (Inst); NeoImmuneTech (Inst); Neovia Oncology (Inst); Nextpoint (Inst); Novartis (Inst); Nuvalent, Inc. (Inst); OncoC4 (Inst); Palleon Pharmaceuticals (Inst); Pfizer (Inst); Pierre Fabre (Inst); PMV Pharma (Inst); Prelude Therapeutics (Inst); Puma Biotechnology (Inst); RasCal (Inst); Regeneron (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Shanghai Junshi BioSciences (Inst); Shattuck Labs (Inst); Silicon Therapeutics (Inst); Summit Therapeutics (Inst); Systimmune (Inst); Taiho Oncology (Inst); TCR2 Therapeutics (Inst); Tempest Therapeutics (Inst); TheRas (Inst); Tizona Therapeutics, Inc. (Inst); Vividion Therapeutics (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech; Incyte; Merck; Pfizer; Sanofi
 
James Chih Hsin Yang
Honoraria - Amgen (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo/Astra Zeneca (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst)
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); Amgen (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); BioNTech SE (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Janssen Oncology (Inst); Lilly (Inst); MSD Oncology (Inst); MSD Oncology (Inst); Takeda (Inst)
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Dizal Pharma; Janssen Oncology; Merck KGaA; MSD Oncology; Takeda
 
Masahiro Tsuboi
Honoraria - Amgen KK; AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi-Sankyo; Johnson & Johnson; Lilly Japan; Medtronic; MSD K.K; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; AstraZeneca Japan; Chugai Pharma; MiRXES; MSD; Novartis
Research Funding - AstraZeneca Japan (Inst); Bristol-Myers Squibb KK (Inst); Johnson & Johnson/Eticon (Inst); Merck (Inst); MiRXES (Inst); Ono Pharmaceutical (Inst)
 
Benjamin Besse
Honoraria - Abbvie (Inst); Helios Medical Communications Ltd (Inst); OSE Immunotherapeutics (Inst); Takeda (Inst)
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); beijin avistone (Inst); BioNTech SE (Inst); Bristol-Myers Squibb (Inst); CureVac (Inst); F. Hoffmann LaRoche (Inst); Foghorn Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD (Inst); OncoC4 (Inst); PharmaMar (Inst); Regeneron (Inst); Sanofi/Aventis (Inst); SERVIER (Inst); Tubulis GmbH (Inst)
Research Funding - Amgen (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); BeiGene (Inst); CureVac (Inst); Daiichi Sankyo Europe GmbH (Inst); Genmab (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); OSE Immunotherapeutics (Inst); Prelude Therapeutics (Inst); Sanofi (Inst)
 
Nivedita Sharma
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Patricia Maeda
Employment - Bayer; Lilly
Stock and Other Ownership Interests - Bayer; Lilly
Travel, Accommodations, Expenses - Lilly
 
Patrick Peterson
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Bente Frimodt-Moller
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Yi Yang
No Relationships to Disclose
 
Alexander Drilon
Stock and Other Ownership Interests - mBrace; Treeline Biosciences
Honoraria - Answers in CME; AstraZeneca; Bristol Myers Squibb Foundation; Clinical Care Options/NCCN; i3 Health; Ignyta/Genentech/Roche; Liberum; Loxo/Bayer/Lilly; OncLive/MJH Life Sciences; PER; Remedica; Research to Practice
Consulting or Advisory Role - Anheart Therapeutics; Axis Pharma; Bayer; Boundless Bio; Clinical Care Options; EcoR1 Capital; EMD Serono/Merck; Journal of the National Comprehensive Cancer Network; Liberum; Lilly; Med Learning; Medscape; Melendi; Monte Rosa Therapeutics; MORE Health; Novartis; Nuvalent, Inc.; Ology Medical Education; PeerView; Repare Therapeutics; touchIME; Treeline Biosciences; Zymeworks
Patents, Royalties, Other Intellectual Property - Osimertinib Selpercatinib; Wolters Kluwer (Royalties for Pocket Oncology)
Other Relationship - Anheart Therapeutics (Inst); Bayer (Inst); Boundless Bio (Inst); Bristol Myers Squibb Foundation (Inst); Exelixis (Inst); Lilly (Inst); Nuvalent, Inc. (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (Inst); Triana (Inst)
 
Yi-Long Wu
Honoraria - AstraZeneca; BeiGene Beijing; Boehringer Ingelheim; Bristol-Myers Squibb/China; Hengrui Pharmaceutical; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Roche; Takeda
Research Funding - BMS (Inst); Boehringer Ingelheim (Inst); Pfizer (Inst); Roche (Inst)